Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?

• Published in: Hematological oncology Vol. 40; no. 5; pp. 835 - 842
• Main Authors: D’Arena, Giovanni, Sgambato, Alessandro, Volpe, Silvestro, Coppola, Giuseppe, Amodeo, Rachele, Tirino, Virginia, D’Auria, Fiorella, Statuto, Teodora, Valvano, Luciana, Pietrantuono, Giuseppe, Deaglio, Silvia, Efremov, Dimitar, Laurenti, Luca, Aiello, Antonella
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.12.2022
• Subjects: Chemotherapy; Chronic lymphocytic leukemia; Flow cytometry; Immunotherapy; Leukemia; measurable residual disease; measurable residual disease; flow cytometry; chronic lymphocytic leukemia
• ISSN: 0278-0232; 1099-1069; 1099-1069
• DOI: 10.1002/hon.3037

Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection.